期刊文献+

胃肠间质瘤的临床特点及影响预后的因素分析 被引量:1

Clinical Features and Prognostic Factors of Gastrointestinal Stromal Tumor
下载PDF
导出
摘要 目的 探讨胃肠间质瘤的临床特点,分析影响其预后的因素.方法 收集我院2009-02~ 2013-03间收治的46例胃肠间质瘤患者的临床资料,回顾性分析其临床特点及影响预后因素.结果 胃肠间质瘤以中年人发病多见,发生部位以胃部较多占58.60%,小肠占26.09%;肿瘤直径>5 em者较多为67.39%;核分裂像<5/50为71.74%,CD117阳性率为78.26%;不同恶性危险程度胃肠间质瘤患者中,高度危险者1、2、3年存活率(60.00%、0、0)明显低于极低度者(100%、100%、90.00%),差异具有统计学意义(P<0.05);而1、2、3年患者存活率分别为89.13%、78.26%、67.39%,差异无统计学意义(P>0.05).其预后在年龄、性别等方面差异无统计学意义(P>0.05);而在肿瘤部位、肿瘤直径、核分裂像、CD117方面差异有统计学意义(P<0.05).结论 肿瘤部位、肿瘤大小、肿瘤性质、核分裂相数目、CD117及术后辅助治疗是术后患者预后的重要指标,其中肿瘤大小、性质及辅助治疗是影响其预后的重要因素. Objective To investigate the clinical features of gastrointestinal stromal tumors, and to analyze the factors affecting the prognosis. Methods Collecting clinical data in 46 cases with gastrointestinal stromal tumors in the hospital from February, 2009 to March, 2013, and retrospectively analyzing the clinical characteristics and prognostic factors. Results Gastrointestinal stromal tumors were common in middle - aged people, with more occurance in stomach, accounting for 58.60% , intestine accounting for 26.09% ; tumor diameter 〉 5cm accounting for 67. 39% ; mitotic count 〈 5/50 accounting for 71.74% , and CDll7 positive rate accounting for 78.26% ; among different degrees of risk of malignant gastrointestinal stromal tumor patients, 1 to 3 years survival rates of high - risk persons were 60% , 0 and 0, which were significantly lower than the low degree with 100%, 100% and 90% ,with statistically significant difference (P 〈 0. 05 ) ; while 1 to 3 year patient survival rates were 89. 13%, 78.26% and 67. 39% , with no statistically significant difference( P 〉 0.05 ). The prognosis in age, gender and other aspects of the difference was not statistically significant ( P 〉 0. 05 ) ; while differences in the tumor site, tumor size, mitotic, CDI17 side difference were statistically significant (P 〈0. 05). Conclusion Tumor location, tumor size, nature, number of mitotic figures, CD117 and postoperative adjuvant therapy are important prognostic indicators. Among them, tumor size, nature and adjuvant therapy is an important factor affecting the prognosis.
出处 《黑龙江医学》 2014年第3期259-260,共2页 Heilongjiang Medical Journal
关键词 胃肠间质瘤 临床特点 预后 影响因素 Gastrointestinal stromal tumor Clinical feature Prognosis Influencing factor
  • 相关文献

参考文献5

  • 1冯强,黄振,裴伟,赵东兵,蔡建强.27例直肠胃肠间质瘤临床特点及预后分析[J].中华医学杂志,2013,93(18):1415-1417. 被引量:9
  • 2E Wardelmann P,Hohenberger P,Reichardt S,et al.Gastrointestinal stromal tumors of the stomach.Updates and differences compared to other locations[J] .Der Pathologe,2010,31 (3):195- 198.
  • 3王彬,钟宇新,黄帅,郑朝旭,袁兴华.117例胃肠道间质瘤的预后影响因素分析[J].中国肿瘤临床与康复,2011,18(1):36-39. 被引量:6
  • 4Christopher A,Marshall,Benjamin J,et al.Endoscopic removal of small gastrointestinal stromal tumors:can we GIST-ify the risk?[J] .Digestive Diseases and Sciences,2010,55 (7):1815 - 1817.
  • 5Camille L Hancock,Friesen,Mark,et al.Follow-up of tetralogy of Fallot patients:tertiary centre versus satellite clinic[J] .Cardiology in the Young,2011,21 (4):444 - 453.

二级参考文献23

  • 1陈利,郭文.胃间质瘤的诊断和治疗进展[J].中国实用内科杂志,2006,26(2):232-234. 被引量:24
  • 2Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis [ J]. Ann Surg Oncol, 2008,15 ( 1 ) :52-59.
  • 3Samiian L, Weaver M, Velanovich V. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up[J]. Am Surg, 2004,70(3) :187-191 ; discussion 191- 192.
  • 4DeMatteo liP, Lewis JJ, Leung D, et al. Two hundred gastroin- testinal stromal tumors: recurrence patterns and prognostic factors for survival[ J]. Ann Surg, 2000,231 ( 1 ) :51-58.
  • 5Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009,373(9669) :1097-1104.
  • 6Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors : A consensus approach [ J ]. Hum Pathol, 2002,33 (5) :459-465.
  • 7Nakajima K, Nishida T, Takahashi T, et al. Partial gastrectomy using natural orifice translumenal endoscopic surgery (NOTES) for gastric submueosal tumors: early experience in humans[ J]. Surg Endosc, 2009 [ Epub ahead of print ].
  • 8Clary BM, DeMatteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison [ J ]. Ann Surg Oncol, 2001,8 ( 4 ) : 290-299.
  • 9Blanke CD, Demetr/GD, yon MM, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [ J ]. J Clin Oncol, 2008,26(4) :620-625.
  • 10Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stro- mal tumors expressing the kit receptor tyrosine kinase: S0033 [J].J Clin Oncol, 2008,26(4) :626-632.

共引文献13

同被引文献17

  • 1Mietnen M, Lasnta J.Gastrointestinal stromal tumors (GISTs) : defini- tion, occurrence, pathology, differential diag-nosis and molecular genetics[ J ].Pol J Pothol, 2003,54( 1 ) : 3-24.
  • 2Tryggvason G,Kristmundsson T,OrvarK,et al.Clinical study on gas- trointestinal stromal tumor(GIST) in Iceland, 1990-2003[J].Dig Dis Sci, 2007,52(9 ) : 2249-2253.
  • 3Fletcher CDM, Bridge JA, Hogrndoorn PCW, et at.WHO classfica- tion of tumours of sole tissue and bone[M].dth edition,Lynn,2013: 164-167.
  • 4Corless CL.Gastrointestinal stromal tumors:what do we know now[Jl. Mod Pathol, 2014, 27 Suppl 1 :S1-S16.
  • 5Beadling C,Patterson J,Justusson E,et akGene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA [ J I.C ancer Med, 2013,2 ( 1 ) : 21-31.
  • 6Fletcher CDM,bridge JA, Hogendoorn PCW,et, at.WHO classifica- tion of tumours of sole tissues and bone EM].4th edition,Lyon;IARC Press, 2013 : 163-167.
  • 7Miettinen M,Sobin LH,Sarlomo-Rikala M.Immunohistoehemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117(KIT)[J].Mod Pathol,2000, 13(10): 1134- 1142.
  • 8Fletcher CD, Bmrnan J J, Corless C, et al.Diagnosis of gastrointestinal stromal tumors: a consensus approach [ J ].Hum Pathol, 2002,33 (5) : 459-465.
  • 9Miettinen M, Lasota J.KIT(CD 117 ):a review on expression in normal and neoplastic tissues,and mutations and their elinieopathologic correla- tion [J]Appl lmmunohistochenl Mol Morphol, 2005,13 (3) : 205-220.
  • 10Ni S,Huang D,Chen X,et al.c-kit geue mutation and CD117 erpres- sion in human anorectal melanomas~J].Hum Pathol, 2012,43(6): 801-807.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部